Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6D94

Crystal structure of PPAR gamma in complex with Mediator of RNA polymerase II transcription subunit 1

Summary for 6D94
Entry DOI10.2210/pdb6d94/pdb
DescriptorPeroxisome proliferator-activated receptor gamma, Mediator of RNA polymerase II transcription subunit 1, (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid, ... (4 entities in total)
Functional Keywordsnuclear receptor, transcription factor, super agonist, ligand binding domain, coactivator, med1, dna binding protein, dna binding protein-agonist complex, dna binding protein/agonist
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains2
Total formula weight37263.03
Authors
Mou, T.C.,Chrisman, I.M.,Hughes, T.S.,Sprang, S.R. (deposition date: 2018-04-27, release date: 2019-05-01, Last modification date: 2023-10-25)
Primary citationNemetchek, M.D.,Chrisman, I.M.,Rayl, M.L.,Voss, A.H.,Hughes, T.S.
A structural mechanism of nuclear receptor biased agonism.
Proc.Natl.Acad.Sci.USA, 119:e2215333119-e2215333119, 2022
Cited by
PubMed Abstract: Efforts to decrease the adverse effects of nuclear receptor (NR) drugs have yielded experimental agonists that produce better outcomes in mice. Some of these agonists have been shown to cause different, not just less intense, on-target transcriptomic effects; however, a structural explanation for such agonist-specific effects remains unknown. Here, we show that partial agonists of the NR peroxisome proliferator-associated receptor γ (PPARγ), which induce better outcomes in mice compared to clinically utilized type II diabetes PPARγ-binding drugs thiazolidinediones (TZDs), also favor a different group of coactivator peptides than the TZDs. We find that PPARγ full agonists can also be biased relative to each other in terms of coactivator peptide binding. We find differences in coactivator-PPARγ bonding between the coactivator subgroups which allow agonists to favor one group of coactivator peptides over another, including differential bonding to a C-terminal residue of helix 4. Analysis of all available NR-coactivator structures indicates that such differential helix 4 bonding persists across other NR-coactivator complexes, providing a general structural mechanism of biased agonism for many NRs. Further work will be necessary to determine if such bias translates into altered coactivator occupancy and physiology in cells.
PubMed: 36469765
DOI: 10.1073/pnas.2215333119
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.9 Å)
Structure validation

229183

PDB entries from 2024-12-18

PDB statisticsPDBj update infoContact PDBjnumon